
Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy. The …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

